JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 2005; 46:1249-1257, doi:10.1016/j.jacc.2005.06.056 (Published online 10 September 2005).
© 2005 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
j.jacc.2005.06.056v1
46/7/1249    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (14)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mallat, Z.
Right arrow Articles by Tedgui, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mallat, Z.
Right arrow Articles by Tedgui, A.

CLINICAL RESEARCH: ACUTE CORONARY SYNDROMES

Circulating Secretory Phospholipase A2 Activity Predicts Recurrent Events in Patients With Severe Acute Coronary Syndromes

Ziad Mallat, MD, PhD*,*, Ph. Gabriel Steg, MD, PhD{dagger}, Joëlle Benessiano, MD, PhD{ddagger}, Marie-Laure Tanguy, PhD§, Keith A. Fox, FESC||, Jean-Philippe Collet, MD, PhD, Omar H. Dabbous, MD, MPH#, Patrick Henry, MD**, Kathryn F. Carruthers, MPhil||, Anne Dauphin, MSc{ddagger}, Carla Sibella Arguelles, MSc{ddagger}, Joëlle Masliah, PhD{dagger}{dagger}, Bénédicte Hugel, PhD{ddagger}{ddagger}, Gilles Montalescot, MD, PhD, Jean-Marie Freyssinet, PhD{ddagger}{ddagger}, Bernard Asselain, PhD§ and Alain Tedgui, PhD*

* Institut National de la Santé et la Recherche Médicale, (INSERM U541), Institut Fédératif de Recherche (IRF) "Circulation," Paris, France
{dagger} Service de Cardiologie, Hôpital Bichat, Paris, France
{ddagger} Centre d’Investigation Clinique, CIC 07, Hôpital Bichat, Paris, France
§ Département de Biostatistiques, Institut Curie, Paris, France
Service de Cardiologie, Hôpital Pitié-Salpêtrière, Paris, France
** Service de Cardiologie, Hôpital Lariboisière, Paris, France
{dagger}{dagger} Service de Biochimie, Hôpital St. Antoine, Paris, France
{ddagger}{ddagger} Institut d’Hématologie et d’Immunologie, Faculté de Médecine, Université Louis Pasteur, Strasbourg, and INSERM U143, Le Kremlin-Bicêtre, France
|| Cardiovascular Research Unit, Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom
# University of Massachusetts Medical School, Worcester, Massachusetts

Manuscript received March 30, 2005; revised manuscript received May 25, 2005, accepted June 6, 2005.

* Reprint requests and correspondence: Dr. Ziad Mallat, Inserm U541, Hôpital Lariboisière, 75010 Paris, France. (Email: mallat{at}larib.inserm.fr).

OBJECTIVES: The purpose of this study was to determine the prognostic value of circulating secretory phospholipase A2 (sPLA2) activity in patients with acute coronary syndromes (ACS).

BACKGROUND: The plasma level of type IIA sPLA2 is a risk factor for coronary artery disease (CAD) and is associated with adverse outcomes in patients with stable CAD. The prognostic impact of sPLA2 in patients with ACS is unknown.

METHODS: Secretory phospholipase A2 antigen levels and activity were measured in plasma samples of 446 patients with ACS, obtained at the time of enrollment.

RESULTS: Baseline sPLA2 activity was associated with the risk of death and myocardial infarction (MI). The unadjusted rate of death and MI increased in a stepwise fashion with increasing tertiles of sPLA2 activity (p < 0.0001). The association remained significant in the subgroup of patients who had MI with ST-segment elevation (p = 0.014) and the subgroup of patients who had unstable angina or non–ST-segment elevation MI (p < 0.002). After adjustment for clinical and biological variables, the hazard ratios for the combined end point of death or MI in the third tertile of sPLA2 compared with the first and second tertiles was 3.08 (95% confidence interval, 1.37 to 6.91, p = 0.006).

CONCLUSIONS: A single measurement of plasma sPLA2 activity at the time of enrollment provides strong independent information to predict recurrent events in patients with ACS.

Abbreviations and Acronyms
  ACS = acute coronary syndromes
  CAD = coronary artery disease
  CRP = C-reactive protein
  GRACE = Global Registry of Acute Coronary Events
  hsCRP = high-sensitivity CRP
  IL = interleukin
  MI = myocardial infarction
  NSTEMI = non–ST-segment elevation MI
  STEMI = ST-segment elevation MI
  sPLA2 = secretory type II phospholipase A2
  UA = unstable angina




This article has been cited by other articles:


Home page
Eur Heart JHome page
D. Divchev, C. Grothusen, M. Luchtefeld, M. Thoenes, F. Onono, R. Koch, H. Drexler, and B. Schieffer
Impact of a combined treatment of angiotensin II type 1 receptor blockade and 3-hydroxy-3-methyl-glutaryl-CoA-reductase inhibition on secretory phospholipase A2-type IIA and low density lipoprotein oxidation in patients with coronary artery disease
Eur. Heart J., August 2, 2008; 29(16): 1956 - 1965.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
U. J. F. Tietge, N. Nijstad, R. Havinga, J. F. W. Baller, F. H. van der Sluijs, V. W. Bloks, T. Gautier, and F. Kuipers
Secretory phospholipase A2 increases SR-BI-mediated selective uptake from HDL but not biliary cholesterol secretion
J. Lipid Res., March 1, 2008; 49(3): 563 - 571.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
P. T.E. Wootton, N. L. Arora, F. Drenos, S. R. Thompson, J. A. Cooper, J. W. Stephens, S. J. Hurel, E. Hurt-Camejo, O. Wiklund, S. E. Humphries, et al.
Tagging SNP haplotype analysis of the secretory PLA2-V gene, PLA2G5, shows strong association with LDL and oxLDL levels, suggesting functional distinction from sPLA2-IIA: results from the UDACS study
Hum. Mol. Genet., June 15, 2007; 16(12): 1437 - 1444.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
Z. Mallat, J. Benessiano, T. Simon, S. Ederhy, C. Sebella-Arguelles, A. Cohen, V. Huart, N. J. Wareham, R. Luben, K.-T. Khaw, et al.
Circulating Secretory Phospholipase A2 Activity and Risk of Incident Coronary Events in Healthy Men and Women: The EPIC-NORFOLK Study
Arterioscler. Thromb. Vasc. Biol., May 1, 2007; 27(5): 1177 - 1183.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
W. Koenig and N. Khuseyinova
Biomarkers of Atherosclerotic Plaque Instability and Rupture
Arterioscler. Thromb. Vasc. Biol., January 1, 2007; 27(1): 15 - 26.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
R. P. Giugliano and E. Braunwald
The Year in Non-ST-Segment Elevation Acute Coronary Syndromes
J. Am. Coll. Cardiol., July 18, 2006; 48(2): 386 - 395.
[Full Text] [PDF]


Home page
CirculationHome page
E. J. Armstrong, D. A. Morrow, and M. S. Sabatine
Inflammatory Biomarkers in Acute Coronary Syndromes: Part III: Biomarkers of Oxidative Stress and Angiogenic Growth Factors
Circulation, February 28, 2006; 113(8): e289 - e292.
[Full Text] [PDF]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2005 by the American College of Cardiology Foundation.